Calithera Biosciences Inc (NASDAQ:CALA) – Equities research analysts at William Blair issued their Q1 2019 earnings estimates for shares of Calithera Biosciences in a research report issued to clients and investors on Friday. William Blair analyst M. Phipps forecasts that the biotechnology company will earn ($0.49) per share for the quarter. William Blair also issued estimates for Calithera Biosciences’ Q2 2019 earnings at ($0.59) EPS, Q3 2019 earnings at ($0.61) EPS and Q4 2019 earnings at ($0.64) EPS.
Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.09). Calithera Biosciences had a negative net margin of 107.21% and a negative return on equity of 17.49%. The firm had revenue of $7.24 million during the quarter, compared to analyst estimates of $7.28 million. During the same period last year, the business posted ($0.45) EPS.
Shares of Calithera Biosciences (CALA) traded down $0.30 during trading hours on Monday, hitting $7.12. The company had a trading volume of 445,060 shares, compared to its average volume of 567,439. The stock has a market capitalization of $263.41, a PE ratio of -8.74 and a beta of 2.49. Calithera Biosciences has a one year low of $6.57 and a one year high of $20.05.
A number of institutional investors have recently modified their holdings of CALA. Jane Street Group LLC bought a new stake in Calithera Biosciences during the fourth quarter worth $103,000. Lazard Asset Management LLC bought a new stake in Calithera Biosciences during the fourth quarter worth $167,000. Trexquant Investment LP bought a new stake in Calithera Biosciences during the third quarter worth $168,000. Acadian Asset Management LLC lifted its holdings in Calithera Biosciences by 1,279.5% during the fourth quarter. Acadian Asset Management LLC now owns 21,686 shares of the biotechnology company’s stock worth $181,000 after acquiring an additional 20,114 shares during the period. Finally, Ellington Management Group LLC bought a new stake in Calithera Biosciences during the fourth quarter worth $191,000. Institutional investors and hedge funds own 68.91% of the company’s stock.
TRADEMARK VIOLATION WARNING: “William Blair Weighs in on Calithera Biosciences Inc’s Q1 2019 Earnings (CALA)” was posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.themarketsdaily.com/2018/03/14/william-blair-weighs-in-on-calithera-biosciences-incs-q1-2019-earnings-cala.html.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.